
Aurinia Pharmaceuticals (AUPH) Stock Forecast & Price Target
Aurinia Pharmaceuticals (AUPH) Analyst Ratings
Bulls say
Aurinia Pharmaceuticals is projected to generate significant risk-adjusted product revenues, starting at $243.7 million in 2025 and increasing to $932.3 million by 2033. Additionally, the company’s potential aritinercept product could contribute risk-adjusted revenues of $15.4 million in 2030, with expectations of growth to $281.6 million by 2033, contingent upon successful launch and market penetration. Furthermore, the anticipated positive impact from the 2024 ACR LN guidelines is expected to accelerate the growth of LUPKYNIS, heralding a new phase of expansion for the company.
Bears say
Aurinia Pharmaceuticals Inc has faced challenges in gaining traction with its lead product, LUPKYNIS, which may lead to slower revenue growth than anticipated in a competitive biopharmaceutical sector. The company's development pipeline, while promising, is still in the early stages, which presents potential risks related to regulatory approval and market entry, impacting investor confidence. Additionally, recurring expenses related to research and development efforts, coupled with limited financial reserves, raises concerns about the company's ability to sustain operations and fund growth initiatives.
This aggregate rating is based on analysts' research of Aurinia Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Aurinia Pharmaceuticals (AUPH) Analyst Forecast & Price Prediction
Start investing in Aurinia Pharmaceuticals (AUPH)
Order type
Buy in
Order amount
Est. shares
0 shares